BPC-157 Dosage, Dosing & Dosage Chart Explained

If you have searched for a BPC-157 dosage chart, you have probably noticed something frustrating: every source gives a different number, almost none of them cite a human study, and no two protocols agree. That inconsistency is not a gap in your research. It reflects the actual state of the science.

Here is the direct answer most people are looking for. There is no established, validated human dosing standard for BPC-157. No regulatory authority has approved it for any human indication, and as of late 2026, there are still no published randomized controlled trials of BPC-157 in humans for any condition. The dosing figures circulating online are not clinical guidelines. They are extrapolations from rodent studies, vendor marketing, and user reports.

This guide explains what the research genuinely supports, why weight-based BPC-157 dosing charts are not built on human data, and what a responsible clinical conversation about peptides looks like. It also explains where the science stops and where personal judgment, marketing, and anecdote tend to fill the silence, because recognizing that boundary is the most useful skill for anyone researching an unapproved compound.

At Dr. Rogers Centers, an integrative internal medicine and gynecology practice in San Antonio, longevity and recovery care is approached through individual evaluation rather than fixed protocols, and that framing matters here more than any number on a chart.

This article is educational. It does not provide dosing instructions, and nothing here should be used to self-administer any peptide. Decisions about peptide therapy belong in a conversation with a licensed clinician who knows your medical history.

What Is BPC-157?

BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide, meaning a chain of fifteen amino acids, based on a sequence identified within a protein found in human gastric juice.

This origin story is often misused. People hear "naturally occurring in the stomach" and assume inherent safety. The distinction matters: the parent protein exists in low concentration in the stomach and acts locally there. The product sold to consumers is a synthetically manufactured peptide, typically administered under the skin, into muscle, into a joint, or intravenously, often repeatedly over weeks. Those are fundamentally different exposures, and conflating them is one of the most common misconceptions in online discussion of this compound.

Interest in BPC-157 comes almost entirely from preclinical work. In animal models, researchers have reported effects on angiogenesis, growth factor signaling, and inflammatory cytokine activity, with improved outcomes in experimentally induced tendon, ligament, muscle, bone, and gastrointestinal injury. Much of this literature originates from a single research group in Croatia and dates back to the 1990s.

Those are mechanisms and animal findings. They are not demonstrated human benefits, and the difference between the two is the entire subject of this article.

Is There a Standard BPC-157 Dosage?

No. There is no universally accepted or clinically validated BPC-157 dosage in humans.

A standard dose in medicine is not a number someone chooses. It emerges from dose-ranging studies, pharmacokinetic characterization, safety monitoring across large populations, and controlled trials comparing outcomes at different doses. That body of work has not been done for BPC-157.

A 2026 narrative review described the human pharmacokinetic profile of BPC-157 as critically undercharacterized. In plain terms, researchers do not have reliable published data on how much reaches circulation by different routes, how long it persists, or how exposure scales with the amount administered. Without that foundation, a dosing standard cannot exist, no matter how confidently a number is presented.

This is why the precise-sounding protocols found across forums and vendor pages should raise suspicion rather than confidence. Precision that is not derived from data is simply formatting dressed up as science.

BPC-157 Dosing: What Human Research Actually Shows

The honest summary is that the human evidence base is very small.

A systematic review published in 2025 focused on orthopedic sports medicine applications screened 544 articles. Of those, exactly one human clinical study met the inclusion criteria. That single figure illustrates the gap between how widely BPC-157 is discussed online and how little it has actually been studied in people.

A separate 2025 narrative review in Current Reviews in Musculoskeletal Medicine, titled "Regeneration or Risk?", searched six databases and reached a similar conclusion: despite substantial preclinical evidence, the human evidence base remains inadequate to support clinical recommendations. The authors called for properly designed randomized controlled trials before BPC-157 can be treated as an evidence-based therapy for any condition.

The most cited human safety data comes from a 2025 pilot study by Lee and Burgess, which examined intravenous BPC-157 infusion in two healthy adults. The investigators reported the infusions were well tolerated with no adverse biomarker effects. The authors themselves acknowledged that a two-person study cannot establish safety at scale, and they described it as a starting point for further research rather than a conclusion.

There is also a small case series from 2021 involving intra-articular injection for knee pain, in which no adverse effects were reported, though adverse event screening was not described in detail in the published account.

That is close to the full extent of published human work. It is nothing, but it is nowhere near a dosing framework, and none of it should be converted into a personal protocol without the involvement of a physician who understands both the compound and the individual.

Why study doses are not recommendations

When a number appears in a research paper, it is tied to a specific route, a specific formulation, a specific screened population, a specific monitoring setup, and a specific research question. Detaching that number and applying it to yourself at home removes every one of those controls. A dose observed in a two-person intravenous safety pilot tells you very little about subcutaneous use in an unscreened individual with an injury and a medication list, and treating the two as interchangeable is a meaningful source of risk that gets lost in casual online summaries.

BPC-157 Dosage Chart: An Evidence Context Table

A conventional dosing chart would be misleading here, because it would imply a validated schedule that does not exist. The table below does something more useful: it maps what each category of evidence actually supports, and where it stops.

Read across that table, and a pattern emerges. The strength of the evidence is inversely related to the confidence of the dosing claim. The most specific numbers tend to come from the least reliable sources, and the categories with the strongest methodology are also the ones offering the least in the way of a usable number.

Is BPC-157 Dosage Based on Body Weight?

This question drives a lot of searches for a BPC-157 dosage chart by weight, so it deserves a direct answer: there is no validated human weight-based dosing formula for BPC-157.

Weight-based dosing is legitimate in medicine, but it is earned. It requires pharmacokinetic studies demonstrating that exposure scales predictably with body mass, followed by trials confirming that the scaled dose behaves as expected across a range of body sizes. None of that work has been published for BPC-157 in humans, which means any weight-based figure you encounter is an assumption rather than a finding.

The mcg-per-kilogram charts circulating online are typically reverse-engineered from animal study doses using allometric scaling. That conversion is a rough planning tool used by researchers to select a starting dose for a first-in-human trial. It is not a patient dosing instrument, and the scientists who use it treat the output as a hypothesis to be tested under controlled conditions, not as an answer ready for personal use.

Body weight is also not the only variable that would matter. Route of administration, formulation, peptide purity, the target tissue, kidney and liver function, and concurrent medications would all influence exposure and risk in a properly designed study. A chart that reduces all of that complexity to a single number in a weight column is projecting a level of precision the science has not actually produced.

BPC-157 Protocol: Why Online Recommendations Differ So Much

If you compare five BPC-157 protocols online, you will likely find five different answers. The variation is explainable, and understanding the sources of it is more useful than trying to identify the "right" one.

• Route of administration. Subcutaneous, intramuscular, intra-articular, oral, and intranasal preparations behave very differently, and human absorption data for most routes is thin or absent.

• Treatment goal. Protocols aimed at a tendon complaint, a gut complaint,nt or general recovery are often presented differently, despite no controlled human evidence establishing indication-specific dosing.

• Formulation and concentration. Reconstitution volume changes what a given mark on a syringe represents, which is a common source of substantial error.

• Product quality. Purity and actual peptide content vary between unregulated suppliers, so the same stated dose may not be the same delivered dose.

• Evidence source. Some figures derive from animal research, some from a clinician’s practice experience, and many from user reports repeated until they sound authoritative.

• Duration and cycling. Cycle lengths and rest periods vary widely across sources and are not grounded in published human outcome or safety data.

This is why copying another person’s protocol is unreliable. You are copying a number while discarding its context, and you have no way to verify the assumptions it was built on, including whether their product contained what the label claimed or whether their body responded the way yours would.

It is also worth stating plainly: more is not better. There is no human evidence that higher doses produce better outcomes, and in the absence of dose-response data, increasing an amount simply increases unquantified risk without any corresponding evidence of greater benefit.

Where BPC-157 Currently Stands With Regulators

BPC-157 is not FDA-approved for any human indication. It has also not been approved by the European Medicines Agency, and no major regulatory body currently recognizes it as a treatment for any condition.

Its compounding status has moved several times recently, which is a frequent source of confusion. In 2023, the FDA placed BPC-157 in Category 2 of the 503A bulk drug substances list, reflecting identified safety concerns centered on immunogenicity and impurities. In April 2026, the agency removed BPC-157 from Category 2 following withdrawal of the nomination, but did not move it to Category 1. That left it in a gray zone: neither explicitly categorized as unsafe for compounding nor authorized for it.

On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding BPC-157 to the 503A Bulks List, one of six peptides recommended that session, and did so against the recommendation in FDA staff briefing materials.

Three points matter about that vote. It is advisory and non-binding. It concerns eligibility for pharmacy compounding, which is a separate question from drug approval. And it does not change current law on its own, because a formal notice-and-comment rulemaking process must follow, which historically has taken a year or more. Because this area is moving quickly, verify the current position through FDA sources rather than relying on any single article, including this one.

For athletes, there is a further consideration worth noting. BPC-157 falls within the World Anti-Doping Agency’s S0 category covering substances with no approval from any governmental health authority for human therapeutic use, which means it remains prohibited in competition regardless of its compounding status or any future rulemaking outcome.

Safety Considerations Before Considering BPC-157

Limited evidence is not the same as demonstrated safety. Absence of reported harm in a handful of very small studies is weak reassurance, because those studies were not designed or sized to detect uncommon, delayed, or cumulative effects that only become visible across a larger population followed over a longer period of time.

Product quality is a distinct and serious concern. Because most BPC-157 sold to consumers is marketed as research-use-only material outside pharmaceutical manufacturing standards, purity, sterility, actual peptide content,nt and contamination are not verifiable by the buyer. The FDA’s original safety concerns specifically included impurities and immunogenicity, meaning the potential for an immune reaction to the peptide itself or to whatever else happens to accompany it in an unregulated preparation.

Injection technique introduces its own risks, including infection, injection site reactions, and dosing errors that arise from incorrect reconstitution or measurement. Anyone considering any injectable therapy should understand that preparation and administration are clinical skills that are typically taught and supervised, not incidental details to be figured out from a video.

Dr. Rogers Centers maintains general patient education on how to prepare an injection for medications prescribed within its programs, which illustrates the level of instruction and oversight that is appropriate before anyone self-administers any injectable substance at home.

Individual health factors matter as well, and they are exactly the kind of thing a chart or a forum post cannot account for. A personal or family history of cancer deserves particular discussion, given that angiogenesis, the growth of new blood vessels, is among the proposed mechanisms of BPC-157 and is also directly relevant to tumor biology. This question has not been resolved in humans in either direction, which is precisely why it warrants a clinical conversation rather than an assumption of safety.

Pregnancy, breastfeeding, active infection, autoimmune conditions, kidney or liver impairment, and existing medication regimens are all reasons to involve a physician before considering any peptide, since each of these can change both the relevant risks and how they should be monitored.

How a Clinician May Approach Peptide Dosing

A responsible clinical process looks quite different from reading a chart. It begins with the problem a patient is actually trying to solve, not with the compound they read about online, and that distinction shapes everything that follows.

A physician would typically start by clarifying the actual goal and confirming the diagnosis, because a tendon complaint, a joint complaint, and a gastrointestinal complaint each have established treatments with genuine evidence behind them that should reasonably be considered and, in many cases, tried before an unapproved compound enters the conversation at all.

For musculoskeletal pain specifically, there are evidence-supported options worth exhausting first. Dr. Rogers Centers’ multispecialty joint care program reflects that stepwise approach to evaluating and treating joint and tendon problems before reaching for experimental therapies.

That stepwise approach usually means starting with a physical examination and, where appropriate, imaging to understand what is actually driving the pain, since a tendon injury, an arthritic joint,t and a nerve irritation can present similarly but respond to very different treatments. Only once that picture is clear does it make sense to discuss which supported therapies, if any, might help, and whether an experimental option is even relevant to the diagnosis in front of the clinician.

Acoustic shockwave therapy is one such supported option, with published evidence for conditions including plantar fasciitis and calcific shoulder tendinitis, discussed further in this overview of StemWave therapy for neck, back and joint pain, which explains how the mechanism differs from an injected peptide and what the supporting research actually covers.

Alongside the physical evaluation, a full medication and supplement review follows, together with relevant personal and family history: prior drug reactions, any cancer history, autoimmune conditions, and organ function, since each of these can meaningfully change the risk calculation for almost any therapy under consideration, experimental or otherwise. A clinician will also want to understand what has already been tried, for how long, and with what result, because that history often points toward the next reasonable step more clearly than any new compound would.

Only after that groundwork would a clinician weigh whether any peptide is appropriate at all, and if so, what the evidence does and does not support, what route and formulation are being considered, what sourcing and quality can actually be verified, what monitoring would be required during use, and what would constitute a clear reason to stop. That sequence, problem first and compound last, is the opposite of how most online protocols are approached.

Peptide therapy appears within the longevity programs at Dr. Rogers Centers, and the broader longevity and advanced recovery services page sets out the range of modalities, from red light therapy to metabolic and performance testing, that may be considered alongside or instead of any single intervention.

Those programs illustrate a broader point: recovery and healthy aging are rarely solved by one substance in isolation. Sleep quality, training load, nutrition, metabolic health, and stress all interact with tissue repair, and a program built around testing and monitoring tends to identify which of those factors is actually the limiting one, rather than assuming a peptide is the missing piece before anything else has been assessed.

Recovery-focused care is also addressed through the practice’s integrative and regenerative care offerings, which are delivered under medical supervision rather than as self-directed protocols researched independently online.

Supervision in this context is not a formality. It means a clinician is tracking what is actually being used, watching for early signs of an adverse reaction, adjusting course if something is not working, and keeping the plan connected to objective measures rather than subjective impressions alone. That kind of oversight is very difficult to replicate when a protocol is sourced from a forum post and followed without anyone else in the loop.

Where nutritional status and the basic building blocks for tissue repair are the limiting factor, amino acid optimization may be a more appropriate and better-supported starting point than an unapproved peptide with an unclear safety profile.

This is a common finding in practice: many people chasing a faster recovery are actually dealing with an underlying deficiency, an unmanaged inflammatory condition, or simply insufficient protein and micronutrient intake to support the repair process their body is already trying to carry out. Addressing that foundation first is unglamorous compared to a peptide protocol, but it is grounded in far more evidence and carries none of the sourcing or purity concerns discussed earlier in this article.

Because these decisions rarely resolve in a single visit, they sit best within an ongoing clinical relationship, which is the model behind the practice’s primary care membership structure, where follow-up and monitoring are built into the plan rather than left to the patient to manage alone.

Key Takeaways

• There is no established human BPC-157 dosage standard. No regulator has approved it for any human indication.

• No randomized controlled trials of BPC-157 in humans have been published for any condition.

• Human evidence consists of a two-person intravenous safety pilot, small uncontrolled case reports, and systematic reviews concluding the evidence is inadequate.

• No validated weight-based dosing formula exists. Weight-based charts online are extrapolated from animal data, not clinically established.

• Online protocols conflict because they vary by route, formulation, product quality, and evidence source, and many carry a commercial interest.

• Higher doses are not supported by evidence as more effective, and increase unquantified risk.

• The regulatory position is actively changing. A July 2026 advisory committee vote recommended BPC-157 for the 503A compounding list, but that is non-binding and separate from drug approval.

• Product quality, purity,and immunogenicity remain genuine concerns with unregulated material.

The Bottom Line

The reason a trustworthy BPC-157 dosage chart does not exist is that the research required to build one has not been done. Preclinical findings are interesting and worth continued study, but interest is not evidence of human benefit, and a mechanism observed in a petri dish or a rodent model is not the same thing as an outcome demonstrated in a person.

If you are dealing with a persistent injury, joint pain,n or a gut issue that has pushed you toward researching peptides, the most productive next step is usually a proper diagnostic workup and a review of treatments that already have human evidence behind them. If peptide therapy still seems worth exploring after that, it belongs in a supervised clinical setting where sourcing, monitoring, and individual risk can actually be accounted for, rather than in a protocol assembled from unrelated sources found online.

To discuss recovery, longevity, or joint concerns with a physician-led team, you can contact Dr. Rogers Centers directly.

Frequently Asked Questions

What is the typical BPC-157 dosage?

There is no typical dosage established by human research. Figures circulating online are drawn from animal studies, vendor materials,  ls and user reports rather than clinical trials, and they conflict substantially with one another. Published human research is too limited to define a typical dose.

Is there a standard BPC-157 dosage?

No. A standard dose requires pharmacokinetic characterization and dose-ranging trials, neither of which has been published for BPC-157 in humans. Reviews in 2025 and 2026 concluded the human evidence base is insufficient to support clinical dosing recommendations.

Is BPC-157 dosage based on body weight?

There is no validated human weight-based dosing formula. Weight-based dosing must be established through pharmacokinetic and clinical studies showing exposure scales predictably with body mass, and that work has not been published for this peptide.

Is there a reliable BPC-157 dosage chart by weight?

No. Charts presenting mcg-per-kilogram figures are typically extrapolated from animal study doses using allometric scaling. Researchers use that method to plan first-in-human studies, not to dose individuals, and you should not treat its output as clinical guidance.

What does BPC-157 dosing research actually show?

Most of the research is preclinical. Human data is limited to a 2025 pilot study of intravenous infusion in two healthy adults reporting good tolerability, a small 2021 intra-articular case series, and systematic reviews concluding the evidence is inadequate for clinical recommendations. There are no published randomized controlled trials.

Is BPC-157 FDA approved?

No. BPC-157 is not FDA-approved for any human indication. Separately, in July 2026 the FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding it to the 503A bulk substances list for pharmacy compounding, but that vote is advisory, is not the same as drug approval, and requires formal rulemaking before it changes anything. Check current FDA sources for the latest position.

How long is a BPC-157 protocol?

Cycle lengths quoted online vary widely and are not based on published human outcome or safety data. No duration has been validated in controlled human research, and long-term safety in humans has not been established.

Is BPC-157 safe?

Safety has not been established in humans. The small studies available reported good tolerability but were far too small to detect uncommon or delayed effects. Additional concerns include product purity, immunogenicity, and contamination in unregulated material. Anyone considering it should discuss individual risk with a qualified healthcare professional.